Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1877188 | 0.80 | CXCR4 (0.49) | CXCR4SIGMAR1CYP2D6CYP3A4 | |
| SCHEMBL29823432 | 0.80 | CXCR4 (0.49) | CXCR4SIGMAR1CYP2D6CYP3A4 | |
| SCHEMBL1871874 | 0.78 | CXCR4 (0.51) | CXCR4SIGMAR1L3MBTL1LTA4HKDM4E | |
| SCHEMBL29823621 | 0.78 | CXCR4 (0.51) | CXCR4SIGMAR1L3MBTL1LTA4HKDM4E | |
| SCHEMBL29823258 | 0.74 | ALDH1A1 (0.43) | CXCR4SIGMAR1L3MBTL1KCNH2HRH3 | |
| SCHEMBL1877208 | 0.74 | ALDH1A1 (0.43) | CXCR4SIGMAR1L3MBTL1KCNH2HRH3 | |
| SCHEMBL27605607 | 0.74 | CXCR4 (0.49) | CXCR4SIGMAR1L3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL29823450 | 0.73 | CXCR4 (0.58) | CXCR4SIGMAR1L3MBTL1SMN1; SMN2CHRM2 | |
| SCHEMBL1878715 | 0.73 | CXCR4 (0.58) | CXCR4SIGMAR1L3MBTL1SMN1; SMN2CHRM2 | |
| SCHEMBL29823344 | 0.73 | CXCR4 (0.51) | CXCR4SIGMAR1KCNH2HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371361-A1 | Methods to mobilize progenitor/stem cells | Genzyme Global S.à.r.l. (LU) | 2011-10-05 | — | — | EP | claimed |
| US-7935692-B2 | Methods to mobilize progenitor/stem cells | GENZYME CORPORATION (US) | 2011-05-03 | — | — | US | claimed |
| US-20100105915-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2010-04-29 | — | — | US | claimed |
| US-20100035941-A1 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | GENZYME CORPORATION | 2010-02-11 | — | — | US | claimed |
| EP-1163238-B1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2006-05-31 | — | — | EP | claimed |
| JP-2003524620-A | — | — | 2003-08-19 | — | — | JP | claimed |
| EP-1163238-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-12-19 | — | — | EP | claimed |
| WO-2000056729-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2000-09-28 | — | — | WO | claimed |
| WO-2025230907-A1 | A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-06 | — | — | WO | disclosed |
| US-20250295698-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS | ENSOMA INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250032549-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | ENSOMA INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20240189387-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | ENSOMA, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-3735412-B1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS | EDIGENE BIOTECHNOLOGY INC (CN) | 2024-02-21 | — | — | EP | disclosed |
| US-20230414565-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | ENSOMA, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20060035829-A1 | Chemokine combinations to mobilize progenitor/stem cells | ANORMED INC. | 2006-02-16 | — | — | US | disclosed |
| US-6987102-B2 | Methods to mobilize progenitor/stem cells | ANORMED, INC. (CA) | 2006-01-17 | — | — | US | disclosed |
| US-20050043367-A1 | Methods to mobilize progenitor/stem cells | ANORMED CORPORATION (CA) | 2005-02-24 | — | — | US | disclosed |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-6750348-B1 | PROTECTIVE EFFECTS AGAINST INFECTION BY HIV THROUGH BINDING TO CHEMOKINE RECEPTORS, INCLUDING CXCR4 AND CCR5;N-(2-PYRIDINYLMETHYL)-N'-(2-(PHENYLUREIDO)ETHYL)-N'-(5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-1,4-BENZENEDIMETHANAMINE | ANORMED, INC. (CA) | 2004-06-15 | — | — | US | disclosed |
| US-20030130250-A1 | Methods to mobilize progenitor/stem cells | ANORMED, INC. (CA) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189387-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | CXCL12, MCL1, MYADM | CXCR4 11/4885SIGMAR1 4776/4885L3MBTL1 357/4885 |
| US-20100105915-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | CXCR4, CCR5, CXCR3 | CXCR4 1/4885SIGMAR1 753/4885L3MBTL1 2369/4885 |
| US-20050043367-A1 | Methods to mobilize progenitor/stem cells | CXCL12, CXCR4, CXCR1 | CXCR4 2/4885SIGMAR1 197/4885L3MBTL1 1492/4885 |
| US-20230414565-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | MCL1, CXCL12, KIT | CXCR4 20/4885SIGMAR1 4683/4885L3MBTL1 1549/4885 |
| US-20060035829-A1 | Chemokine combinations to mobilize progenitor/stem cells | CXCL12, CXCR2, CXCR4 | CXCR4 3/4885SIGMAR1 1845/4885L3MBTL1 2112/4885 |
| US-20100035941-A1 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | CCR2, CXCR4, CXCR2 | CXCR4 2/4885SIGMAR1 144/4885L3MBTL1 2124/4885 |
| US-20250032549-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | CXCL12, CD44, CD47 | CXCR4 7/4885SIGMAR1 4862/4885L3MBTL1 609/4885 |
| US-20030130250-A1 | Methods to mobilize progenitor/stem cells | CXCR4, CXCL12, CXCR2 | CXCR4 1/4885SIGMAR1 233/4885L3MBTL1 1361/4885 |
| US-20250295698-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS | CXCL12, CSF3R, THPO | CXCR4 12/4885SIGMAR1 4856/4885L3MBTL1 553/4885 |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR4, CXCR1 | CXCR4 2/4885SIGMAR1 87/4885L3MBTL1 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.